Lilly and Boehringer’s Trajenta matches glimepiride in delaying cardiovascular events in type 2 diabetes patients
pharmafile | February 15, 2019 | News story | Medical Communications, Research and Development | Boehringer, Eli Lilly, cardiovascular disease, pharma, type 2 diabetes
Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself non-inferior to glimepiride in its ability to prolong the amount of time before the first occurrence of cardiovascular (CV) death, non-fatal myocardial infarction or non-fatal stroke in type 2 diabetes patients.
The CAROLINA trial – the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor – examined the efficacy of Trajenta in 6,033 patients with type 2 diabetes in addition to established CV disease or increased CV risk, compared to glimepiride sulphonylurea and standard of care. It provided the longest evaluation ever of a DPP-4 inhibitor in cardiovascular disease, with a median follow-up of over six years.
“Many guidelines recommend early use of a diabetes treatment with cardiovascular benefit,” commented Dr Waheed Jamal, Corporate Vice President and Head of Cardiovascular & Metabolic Medicine at Boehringer Ingelheim. “When other therapies such as DPP-4 inhibitors are considered for people with type 2 diabetes, physicians need a treatment with an established long-term safety profile. With these results, CAROLINA expands our understanding of the long-term cardiovascular safety of linagliptin, which now has one of the most comprehensive datasets on the cardiovascular safety of a DPP-4 inhibitor.”
Dr Jeff Emmick, Vice President, Product Development at Lilly Diabetes, added: “These data provide further confidence in the well-established safety and tolerability profile of linagliptin for the treatment of adults with type 2 diabetes. Linagliptin is an important option for physicians considering a DPP-4 inhibitor for their patients with type 2 diabetes. Boehringer Ingelheim and Lilly look forward to sharing the full results later this year.”
Matt Fellows
Related Content
Five Facts about cardiovascular disease
1 Cardiovascular disease (CVD) is an umbrella term for conditions affecting the heart and blood …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
